TMS is not a hoax. The first TMS device was FDA-cleared for depression in 2008, Deep TMS followed in 2013, and large sham-controlled trials, including a 2010 NIMH-funded study, show remission rates two to four times higher than sham. Medicare and most insurers cover it. It is not a cure, and roughly a third of patients do not respond.
The skepticism is understandable. TMS sounds strange, it is heavily marketed, it is expensive, and depression trials are famous for large placebo responses. This page walks through what the trials actually found, how the sham conditions were designed, how big the effect is, what TMS cannot do, and why reasonable people still have doubts. You can decide for yourself whether it belongs on your list.
Who it is for
This page is for the patient who has been handed a TMS brochure and wants to know whether the science holds up, for the family member who has read a skeptical forum post, and for anyone who has already spent years and thousands of dollars on treatments that did not work and cannot afford to be fooled again. It is also for clinicians outside psychiatry who are asked about TMS by patients and want a straight summary. The clinical candidates for TMS itself are adults with major depressive disorder that has not responded to at least one antidepressant, adults with OCD that has not responded to an SSRI and therapy, and adults with depression complicated by anxiety. If that is you, the question of whether TMS is real is worth answering carefully, because the answer determines whether a six-week commitment makes sense.
How it works
The claim behind TMS is specific and testable. A magnetic coil placed against the scalp generates brief pulses that induce a small electrical current in the cortex beneath it. Delivered in trains, over weeks, to the left dorsolateral prefrontal cortex, that stimulation changes the activity of a circuit that is reliably underactive in depression. The physics is the same principle as an MRI gradient coil or an induction stove: a changing magnetic field induces current in a conductor, and neurons are conductors. The physiology is observable in the same session: stimulate the motor cortex with the same coil and your thumb twitches, which is how the dose is calibrated for every patient. The hypothesis that repeated stimulation produces lasting antidepressant effects was tested the way any drug is tested, in randomized trials against a sham coil that looks, sounds and feels like the real one but delivers no meaningful current to the brain.
In the first large multisite sham-controlled trial of TMS, 301 medication-free patients with treatment-resistant depression were randomized; at six weeks, 23.9 percent of the active group responded versus 12.3 percent with sham, and remission was 14.2 versus 5.5 percent.
Source: O'Reardon et al., Biological Psychiatry, 2007
The NIMH-funded OPT-TMS trial, run independently of any device manufacturer, randomized 190 patients and found remission in 14.1 percent of active patients versus 5.1 percent with sham, an odds ratio of 4.2.
Source: George et al., Archives of General Psychiatry, 2010
In the Deep TMS pivotal trial of 212 patients, remission at five weeks was 32.6 percent with active treatment versus 14.6 percent with sham, and the difference persisted through 16 weeks.
Source: Levkovitz et al., World Psychiatry, 2015
A meta-analysis of 29 sham-controlled trials with 1,371 patients found response in 29.3 percent of active patients versus 10.4 percent with sham, and remission in 18.6 versus 5 percent, a number needed to treat of six for response.
Source: Berlim et al., Psychological Medicine, 2014
What to expect
If you decide TMS is credible enough to try, the process at Stedfast Psychiatry starts with an evaluation at any of our 13 offices or by video. A psychiatrist confirms the diagnosis, documents the medications you have tried and screens for the few contraindications. Our TMS coordinator handles insurance authorization. Treatment sessions take place at our TMS treatment centers, with Palm Beach Gardens as the primary center. The course is 36 sessions of about 20 minutes each, five days a week for six weeks, then a three-week taper. You are awake, seated and can drive yourself home. We measure your PHQ-9 every week so that you and your psychiatrist can see whether it is working, and we tell you honestly if it is not.
Benefits
- FDA-cleared since 2008, with Deep TMS cleared for depression in 2013, OCD in 2018, smoking cessation in 2020 and anxious depression in 2021
- Tested in randomized sham-controlled trials with thousands of patients, not just open-label case series
- Remission rates two to four times higher than sham across the pivotal trials and meta-analyses
- Covered by Medicare and most major commercial insurers, which require evidence before paying
- No systemic side effects, no sedation, no sexual or weight side effects, and you drive yourself home
Risks and side effects
The honest limits are part of the evidence. About a third of patients do not respond. The most common side effects are scalp discomfort and headache during the first week, which fade for most people. Seizure is the serious risk and it is rare, on the order of one in 30,000 sessions, and we screen for the factors that raise it. TMS does not treat psychotic depression well, is not a substitute for ECT in a medical emergency, and is not cleared for most of the conditions you may see it advertised for online, including autism, dementia and chronic pain. Any clinic that promises a cure or a fixed success rate is overstating what the trials show.
Cost and insurance
Medicare covers TMS for major depressive disorder in Florida and South Carolina when a psychiatrist documents the diagnosis and at least one failed or intolerable antidepressant trial. Commercial plans typically require two to four failed trials and a course of psychotherapy, then issue prior authorization. The fact that payers cover TMS is itself a piece of evidence: insurers review the same trials you are reading about here and conclude that paying for TMS is cheaper than paying for ongoing untreated depression. Self-pay courses cost several thousand dollars, which is one legitimate reason skeptics exist. Our TMS coordinator verifies your coverage before you commit to a schedule.
Why the question comes up
People search for whether TMS is a hoax for good reasons. The treatment involves a magnet on the head, which sounds closer to a wellness gadget than to medicine. Clinics advertise it aggressively, sometimes with success rates that are higher than the trials support. A self-pay course costs as much as a used car. And anyone who has lived with depression knows that hope itself produces short-term improvement, so a treatment that involves daily attention from staff for six weeks could plausibly work by expectation alone.
Those are fair objections. They are also the same objections that the trial designers had, which is why the evidence base for TMS is built on sham-controlled randomized trials rather than testimonials.
The FDA record
The first TMS device was FDA-cleared for major depressive disorder in October 2008, for adults who had not responded to at least one antidepressant in the current episode. Deep TMS, which uses a helmet-mounted H-coil rather than a handheld figure-8 coil, was cleared for depression in 2013. Deep TMS was then cleared for obsessive-compulsive disorder in 2018, for short-term smoking cessation in 2020 and for anxious depression in 2021. Theta burst stimulation, a protocol that delivers a session in about three minutes, was cleared in 2018, and an accelerated multi-session-per-day protocol was cleared in 2022.
Each clearance required the manufacturer to submit controlled data. The FDA pathway for devices is different from the drug approval pathway, which is why the correct term is FDA-cleared rather than FDA-approved, but the central requirement is the same: show that the device does what you say it does, safely, in a trial designed to rule out placebo.
The trials that settled the question
O'Reardon 2007
The first large multisite trial randomized 301 medication-free patients with treatment-resistant depression across 23 sites to active or sham TMS, five days a week for up to six weeks. The sham coil was built to look and sound identical. At six weeks, response on the primary depression scale was 23.9 percent in the active group versus 12.3 percent with sham, and remission was 14.2 percent versus 5.5 percent. Those numbers look modest until you remember that every patient in the trial had already failed at least one antidepressant and was taking no medication at all during the study.
George 2010, the NIMH OPT-TMS trial
Skeptics reasonably point out that manufacturers fund most device trials. The OPT-TMS study was funded by the National Institute of Mental Health, run at four university sites, and used a sham system that delivered a scalp sensation and sound so that patients and raters genuinely could not tell the arms apart. Among 190 patients, remission was 14.1 percent with active TMS versus 5.1 percent with sham. The odds of remission were about four times higher with real stimulation. Patients who finished the blinded phase without remitting were then offered open-label TMS, and about 30 percent of them remitted.
Levkovitz 2015, the Deep TMS pivotal trial
The Deep TMS trial enrolled 212 patients at 20 sites in the United States, Israel, Germany and Canada, all of whom had failed one to four antidepressant trials in the current episode. After five weeks of daily sessions, remission was 32.6 percent with active Deep TMS versus 14.6 percent with sham, and response was 38.4 versus 21.4 percent. The benefit held through a 12-week continuation phase of twice-weekly sessions. This is the trial behind the device Stedfast Psychiatry's TMS program uses.
The meta-analyses
Individual trials can mislead, so the more important evidence is the pooled picture. A 2014 meta-analysis of 29 sham-controlled trials with 1,371 patients found response rates of 29.3 percent active versus 10.4 percent sham and remission rates of 18.6 versus 5 percent, with a number needed to treat of six for response. A 2019 network meta-analysis in the BMJ pooled 81 randomized trials with 4,233 patients and found that high-frequency left prefrontal TMS, Deep TMS, bilateral TMS and theta burst stimulation were each significantly superior to sham. That is a larger and more consistent evidence base than many drugs carry.
How big is the effect, honestly
The trial numbers understate what patients experience in practice, for a specific reason. Trials enroll patients who are often off medication, at a fixed dose of stimulation, for a fixed number of weeks, with blinded raters. Real-world outcomes are better. In a registry of 307 patients treated at 42 clinics in ordinary practice, with most patients continuing their medication, 58 percent responded and 37 percent remitted by clinician rating. Larger Deep TMS registries have reported response rates in the 60 to 75 percent range. The right way to read these numbers is that roughly two thirds of patients get meaningful relief and about a third of all patients reach full remission, after they have already failed medication.
The right way to read the other side is that roughly a third of patients get little or nothing. TMS is a good treatment. It is not a miracle.
| Source | Patients | Active remission | Sham remission |
|---|---|---|---|
| O'Reardon 2007 | 301 | 14.2% | 5.5% |
| George 2010 (NIMH) | 190 | 14.1% | 5.1% |
| Levkovitz 2015 (Deep TMS) | 212 | 32.6% | 14.6% |
| Berlim 2014 meta-analysis | 1,371 | 18.6% | 5.0% |
Why the skeptics exist
Placebo response in depression
Placebo response in antidepressant trials commonly runs 30 to 40 percent on response measures, and that is exactly why the sham arms matter. The sham groups in TMS trials improved too. The treatment effect is the gap between arms, and it is consistent across independent trials, independent funders and different coil designs. A hoax does not replicate.
Cost
A self-pay course can cost several thousand dollars, and a treatment that expensive invites suspicion. The counterweight is that Medicare and nearly every major commercial insurer cover TMS after reviewing the same evidence, because untreated depression costs them more in hospitalizations, emergency visits and disability. Payers are not sentimental.
Marketing
Some clinics advertise 90 percent success rates, promise cures, or offer TMS for conditions it is not cleared for. That kind of marketing damages the credibility of a treatment that does not need it. When you see a claim that is better than the numbers on this page, treat it as a warning sign about the clinic, not as evidence about TMS.
Early history
Before 2007 the published TMS studies were small, used varied protocols, and were sometimes negative. The early skepticism was justified at the time. The field answered it with larger trials, standardized doses and better sham coils. Some online criticism is still quoting the pre-2007 literature.
What TMS does not do
- It does not work for everyone. Roughly one in three patients does not respond.
- It does not work instantly. Most responders notice change in weeks three to five, and some only after the full course.
- It does not cure depression permanently. About a third of responders relapse within a year and may need a repeat course.
- It is not cleared for PTSD, bipolar depression, generalized anxiety on its own, autism, dementia or chronic pain, regardless of how it is advertised.
- It is not a substitute for ECT in psychotic depression, catatonia or a life-threatening emergency.
- It does not replace therapy. The best outcomes in the registries come from patients who continue medication and therapy alongside TMS.
The bottom line
TMS is a real, FDA-cleared, insurance-covered treatment with a sham-controlled evidence base that has been replicated across independent trials for nearly two decades. It helps roughly two thirds of people with depression who have not responded to medication, and it does so without the systemic side effects of drugs. It is also oversold by some of the people who provide it, and it fails for a meaningful minority. Both of those things are true, and a program that tells you only the first half is not being straight with you.
If you want to find out whether TMS makes sense for you, Stedfast Psychiatry's TMS program begins with an evaluation at any of our 13 offices or by video, and our TMS coordinator confirms coverage before you commit. Treatment sessions take place at our TMS treatment centers, with Palm Beach Gardens, 11641 Kew Gardens Ave, Suite 209, as the primary center. Call (561) 437-2199 to schedule a TMS evaluation.
Frequently asked questions
Is TMS FDA-approved?
TMS devices are FDA-cleared, which is the correct term for medical devices; drugs are FDA-approved. The first TMS device was cleared for major depressive disorder in October 2008. Deep TMS was cleared for depression in 2013, OCD in 2018, smoking cessation in 2020 and anxious depression in 2021. A rapid theta burst protocol was cleared in 2018 and an accelerated protocol in 2022. Clearance required the manufacturers to submit randomized sham-controlled trial data.
Could the results just be placebo?
Placebo response is real in depression and the trials were designed around it. Patients in the sham arms sat in the same chair, heard the same clicking and felt a scalp sensation from a sham coil, and did not know which arm they were in. The sham groups improved, as expected, by roughly 5 to 15 percent remission. The active groups improved two to four times as much. The difference between the arms is the treatment effect, and it has been replicated across independent trials.
Why do some people say TMS did nothing for them?
Because for about a third of patients it does not work, and those patients are right to say so. A treatment that helps roughly two thirds of people and fails the rest will generate plenty of negative reviews, especially from people who paid out of pocket. Non-response is more likely with very long current episodes, psychotic features, severe personality disorders, active substance use and heavy benzodiazepine use. We screen for these at the evaluation so that we do not recommend TMS to people it is unlikely to help.
If TMS works, why is it not the first treatment everyone gets?
Cost, logistics and the fact that medication works for many people. An antidepressant costs a few dollars a month and takes two minutes a day. TMS costs thousands of dollars and 36 visits over nine weeks. For a first episode of moderate depression, medication and therapy are the sensible first steps, and most guidelines and insurers position TMS after one or more medication failures. That sequencing is about economics and convenience, not about TMS being weaker.
Is Deep TMS different from the TMS in the trials?
Deep TMS uses a different coil, called an H-coil, built into a helmet, which stimulates a broader and somewhat deeper region of the prefrontal cortex than the figure-8 coil used in the 2007 and 2010 trials. It was tested in its own sham-controlled pivotal trial, published in 2015, with results at least as strong as the earlier studies. Both approaches are FDA-cleared, and network meta-analyses find both effective. Stedfast Psychiatry's TMS program uses Deep TMS.
Do the benefits last, or do you have to keep coming back?
Both are true for different patients. In the largest durability study, about two thirds of responders were still doing well a year after their course without further TMS. The remaining third relapsed, usually within six months, and most of them responded again to a repeat course. Continuing your antidepressant and therapy after TMS lowers the relapse risk. TMS is a treatment for an episode, not a permanent fix, which is the same thing that is true of every other depression treatment.
What conditions is TMS marketed for that it is not cleared for?
You may see TMS advertised for autism, Alzheimer's disease, chronic pain, fibromyalgia, tinnitus, stroke recovery, PTSD, addiction beyond smoking and even athletic performance. Some of these have promising research; none is FDA-cleared for TMS in the United States. We treat the cleared indications: depression, anxious depression, OCD and smoking cessation. We consider carefully selected off-label cases, such as bipolar depression on a mood stabilizer, only after a psychiatrist reviews the evidence with you.
How do I know a TMS clinic is legitimate?
Ask who performs the evaluation and prescribes the treatment: it should be a psychiatrist. Ask which device is used and which indications it is cleared for. Ask how they measure progress; a legitimate program tracks a rating scale such as the PHQ-9 every week. Ask what their realistic response and remission expectations are; honest answers are in the range of 50 to 70 percent response and 30 to 45 percent remission, not 90 percent. And ask whether they bill insurance, since payers audit the documentation.
Where this treatment is offered
Conditions this treats
If you are in crisis, call or text 988 or go to the nearest emergency room. Educational content; individual results vary. Reviewed by Dr. David Husted, board-certified psychiatrist.